

Supplemental Material

Table 3 – Clinical Characteristics, Intensive Care Unit (ICU) Interventions and Outcomes of Patients Admitted to the ICU with COVID-19

Characteristic (n [%] Unless Otherwise Indicated)	Total (n = 288)	Survived hospitalization (n=202)	Died during hospitalization (n=86)	p ^a value
Clinical Characteristics				
Sequential Organ Failure Assessment on admission, median (IQR)	6 (3-9)	6 (3-8)	7 (3-11)	0.074
Troponin-I maximum, median (IQR)	0.11 (0.05-0.42)	0.09 (0.04-0.23)	0.36 (0.08-1.29)	<0.001
B-Natriuretic Peptide maximum, median (IQR)	152 (59-503)	126 (51-399)	371 (106-1,038)	<0.001
D-dimer maximum, median (IQR)	7,287 (2,567-33,784)	6,026 (2108-22,999)	18,740 (5,922-60,000+)	<0.001
Lactic acid maximum, median (IQR)	1.5 (1.1-2.1)	1.4 (1.0-2.0)	1.7 (1.1-2.7)	0.043
C-reactive protein maximum, median (IQR)	262 (117-352)	237 (152-327)	321 (233-389)	<0.001
PaO ₂ /FiO ₂ on ICU admission, median (IQR)	164 (120-248)	172 (128-256)	148 (102-216)	0.011
ICU Interventions				
Corticosteroids	24 (9.8)	17 (9.9)	7 (9.5)	0.938
Adaptive clinical treatment trial (remdesivir and/or placebo)	49 (17.0)	37 (18.3)	12 (14.0)	0.367
Vasopressors	183 (63.5)	115 (56.9)	68 (79.1)	<0.001
Vasopressor days, median (IQR)	4 (2-8)	4 (2-8)	5 (3-9)	0.057
Inotropes	30 (10.4)	13 (6.4)	17 (19.8)	<0.001
Inhaled vasodilator	39 (13.5)	21 (10.4)	18 (20.9)	0.017
Mechanical ventilation	212 (73.6)	140 (69.3)	72 (83.7)	0.011
Ventilator days, median (IQR)	9 (5-14)	9 (5-14)	9 (5-14)	0.505
Any CRRT/HD	77 (26.7)	36 (17.8)	41 (47.7)	<0.001
CRRT/HD days, median (IQR)	17 (12-22)	17 (12-19)	21 (4-23)	0.961
Outcomes				
ICU days, median (IQR)	9 (3-15)	9 (3-16)	8 (4-14)	0.292
Hospital days, median (IQR)	15 (9- 24)	19 (10-27)	11 (7-15)	<0.001

IQR = interquartile range

CRRT = continuous renal replacement therapy

HD = hemodialysis

^a χ^2 or Wilcoxon rank-sum test